Opioid overdose – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030
An opioid overdose occurs when a person has excessive unopposed stimulation of the opiate pathway. This can lead to decreased respiratory effort and possibly death. The frequency of opioid overdose is rapidly increasing. Opiates are frequently prescribed for moderate to severe pain in the US. They are often prescribed alone or in combination with non-steroidal anti-inflammatory drugs or muscle relaxants. Opioids work via the endogenous opioid system by acting as a potent agonist to the mu receptor. This results in a complex cascade of intracellular signals resulting in dopamine release, blockade of pain signals, and a resulting sensation of euphoria. Opioid receptors are located in the brain, spinal cord, and gut. In overdose, there is an excessive effect on the portion of the brain regulating respiratory rate, resulting in respiratory depression and eventually death.
In the USA ~465,000 visits
to the emergency rooms related to opiates in 2019. However more than 20 MN
population of the USA having exposed to opium.
The competitive
landscape of Opioid overdose includes country-specific approved and pipeline
therapies. Any asset/product-specific designation or review and Accelerated
Approval are tracked and supplemented with analyst commentary.
KOLs insights of Opioid
overdose across 8 MM market from the center of Excellence/ Public/ Private
hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Opioid
overdose Market
Forecast: Patient Based Forecast Model (MS. Excel Based Automated
Dashboard) which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
S. No Asset Company Stage
1 Zimhi Adamis
Pharmaceuticals Phase 3
2 Nalmefene HCI Injection Purdue
Pharma L.P. Phase 3
3 OPNT003 Opiant
Pharmaceuticals, Inc. Phase 2
Comments
Post a Comment